Ikarian Capital’s Acceleron Pharma XLRN Stock Holding History

Ikarian Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100,000	Closed	-$12.8M	–	344
2020 Q4	$12.8M	Buy	+100,000	New	+$11.7M	0.56%	42
2020 Q3	–	Sell	-34,500	Closed	-$3.29M	–	232
2020 Q2	$3.29M	Sell	34,500 -282,400	-89%	-$27.2M	0.26%	85
2020 Q1	$28.5M	Buy	+316,900	New	+$24.6M	2.14%	7

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ikarian Capital's XLRN Position: Q2 2020 in Review

Ikarian Capital sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 239,249 shares — an estimated $23.1M sold.

Ikarian Capital first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $21.5M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Ikarian Capital reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Ikarian Capital sold 239,249 Acceleron Pharma shares in Q2 2020, an estimated $23.1M.
Ikarian Capital first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
Ikarian Capital's Acceleron Pharma position peaked at $21.5M in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.